Skip to main content
SpringerLink
Log in

Anaphylactoid reactions associated with bisantrene infusions

  • Clinical
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Nine of ninety-three patients receiving Bisantrene on an every three week schedule developed an anaphylactoid reaction with a variety of symptoms. Most reactions occurred in patients who had multiple exposures to Bisantrene. Investigatiors utilizing Bisantrene in ongoing clinical trials should be aware of this life threatening toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Von Hoff DD, Myers JW, Kuhn J, Sandbach JE, Pocelinko R, Clark G, Coltman CA Jr: Phase I clinical investigation of 9,10-Anthracenedicarboxaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride (CL216942). Cancer Res 41:3118–3121, 1981

    Google Scholar 

  2. Spiegel RJ, Blum RH, Levin M, Pinto CA, Wernz JC, Speyer JL, Hoffman KS, Muggia FM: Phase I clinical trial of 9,10-Anthracene Dicarboxaldehyde (Bisantrene) administered in a five-day schedule. Cancer Res 42:354–358, 1982

    Google Scholar 

  3. Myers JW, Von Hoff DD, Coltman CA Jr, Kuhn JG, Van Echo D, Rivkin S, Pocelinio R: Phase II evaluation of Bisantrene in patients with renal cell carcinoma. Cancer Treat Repts, 1982 (In press)

  4. Alberts DS, Mackel C, Pocelinko R, Salmon SE: Phase I clinical investigation 9,10-Anthracenedicarboxaldehyde Bis [(4,5-dihydro-1H-imidazol-2-yl)hydrazone] Dihydrochloride with correlative in vitro human tumor clonogenic assay. Cancer Res 42:1170–1175, 1982

    Google Scholar 

  5. Yap BS, Yap HY, Blumenschein GR, Bedikian AY, Pocelinko R, Bodey GP: Phase I clinical evaluation of 9,10-An- thracenedicarboxy-aldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (Bisantrene). Cancer Treat Repts 66:1517–1520, 1982

    Google Scholar 

  6. Spiegel RJ, Levin M, Blum R, Speyer J, Wernz J, Pinto C, Muggia F: Phase II trial of daily × 5 Bisantrene in renal cell carcinoma. (Abstract) Proc Am Assoc Cancer Res 23:111, 1982

    Google Scholar 

  7. Scher H, Schwartz S, Yagoda A, Watson RC: Phase II trial of 9,10-Anthracenedicarboxaldehyde Bis [(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride (CL216942) for metastatic hypernephroma. Proc Am Assoc Cancer Res 23:145, 1982

    Google Scholar 

  8. Perry MC, Forastiere AA, Richards F II, Weiss RB, Anbar D: Phase II trial of Anthracenedicarboxaldehyde (ADC) in advanced colorectal cancer: A CALGB study. (Abstract) Proc Am Soc Clin Oncol 1:102, 1982

    Google Scholar 

  9. Yap HY, Yap BS, Blumenschein GR, Barnes B, Schell F, Bodey GP: Bisantrene (CL216942), a promising new drug in the treatment of metastatic breast cancer. (Abstract) Proc Am Assoc Cancer Res 23:147, 1982

    Google Scholar 

  10. Gell PGH, Coombs RRA: In Clinical aspects of immunology. Blackwell Scientific Publications, Oxford, 1975

    Google Scholar 

  11. Weiss RB: Hypersensitivity Reactions to Cancer Chemotherapy. Sem Oncol 9:5–13, 1982

    Google Scholar 

  12. Herman EH, Young RSK: Acute cardiovascular alterations induced by low doses of Adriamycin, Rubidazone, and Daunorubicin in the anesthetized beagle dog. Cancer Treat Repts 63:1771–1779, 1979

    Google Scholar 

  13. Hatfield AK, Hardey L, Abderhalden RT: Chronic urticarial reactions caused by Doxorubicin-containing regimens. Cancer Treat Rep 65:353–354, 1981

    Google Scholar 

  14. Bickers J, Benjamin R, Wilson H, Eyre H, Hewlett J, McCredie K: Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group Study. Cancer Treat Repts 65:427–430, 1981

    Google Scholar 

  15. Alberts D: Personal communication, April 1982

Download references

Author information

Authors and Affiliations

  1. Hematology/Oncology, Wilford Hall Medical Center, Lackland Air Force Base, 78232, San Antonio, TX, USA

    J. William Myers

  2. Department of Medicine, Division of Oncology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, 78284, San Antonio, TX, USA

    Daniel D. Von Hoff, John G. Kuhn, C. Kent Osborne & John F. Sandbach

  3. Department of Clinical Pharmacology, American Cyanamid Company, Medical Research Division, 10965, Pearl River, NY, USA

    Robert Pocelinko (Associate Director)

Authors
  1. J. William Myers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel D. Von Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John G. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Kent Osborne
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John F. Sandbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert Pocelinko
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Myers, J.W., Von Hoff, D.D., Kuhn, J.G. et al. Anaphylactoid reactions associated with bisantrene infusions. Invest New Drugs 1, 85–88 (1983). https://doi.org/10.1007/BF00180195

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00180195

Key words

Search

Navigation